![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Clearance to Roche’s Anti-Mullerian Hormone Test Elecsys
FDA Grants Clearance to Roche’s Anti-Mullerian Hormone Test Elecsys
![FDA_Logo_Blue_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue_2016.gif?t=1578316591&width=430)
The FDA cleared Roche’s anti-mullerian hormone (AMH) assay Elecsys for use in the assessment of ovarian reserve.
The fully-automated device measures the AMH levels in blood samples to assess reproductive potential based on the quality and quantity of egg cells in the ovaries. The fertility test is a standardized approach for evaluating ovarian reserve compared to other options, such as vaginal ultrasound.
Roche secured a CE mark to sell the device in all countries accepting the approval, including European, Middle Eastern and Latina American nations.
Upcoming Events
-
21Oct